Kane Biotech, Inc. (KNE.V)
0.03
0.00 (0.00%)
CAD |
TSXV |
Sep 18, 16:00
Kane Biotech Enterprise Value : 7.260M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 7.260M |
| September 17, 2026 | 7.260M |
| September 16, 2026 | 7.260M |
| September 15, 2026 | 7.260M |
| September 14, 2026 | 7.260M |
| September 11, 2026 | 7.260M |
| September 10, 2026 | 7.260M |
| September 09, 2026 | 7.260M |
| September 08, 2026 | 5.210M |
| September 04, 2026 | 6.235M |
| September 03, 2026 | 7.260M |
| September 02, 2026 | 7.260M |
| September 01, 2026 | 7.260M |
| August 31, 2026 | 6.235M |
| August 28, 2026 | 7.260M |
| August 27, 2026 | 6.235M |
| August 26, 2026 | 6.235M |
| August 25, 2026 | 6.235M |
| August 24, 2026 | 7.260M |
| August 21, 2026 | 7.260M |
| August 20, 2026 | 6.235M |
| August 19, 2026 | 7.260M |
| August 18, 2026 | 7.260M |
| August 17, 2026 | 7.260M |
| August 14, 2026 | 7.260M |
| Date | Value |
|---|---|
| August 13, 2026 | 7.260M |
| August 12, 2026 | 7.260M |
| August 11, 2026 | 5.210M |
| August 10, 2026 | 5.210M |
| August 07, 2026 | 7.260M |
| August 06, 2026 | 7.260M |
| August 05, 2026 | 6.235M |
| August 04, 2026 | 6.235M |
| July 31, 2026 | 6.235M |
| July 30, 2026 | 6.235M |
| July 29, 2026 | 6.235M |
| July 28, 2026 | 6.235M |
| July 27, 2026 | 7.260M |
| July 24, 2026 | 6.235M |
| July 23, 2026 | 6.235M |
| July 21, 2026 | 6.235M |
| July 20, 2026 | 6.235M |
| July 17, 2026 | 6.235M |
| July 16, 2026 | 6.235M |
| July 15, 2026 | 6.235M |
| July 14, 2026 | 6.235M |
| July 13, 2026 | 6.235M |
| July 10, 2026 | 6.235M |
| July 09, 2026 | 6.235M |
| July 08, 2026 | 7.260M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Quest PharmaTech, Inc. | 5.214M |
| BriaCell Therapeutics Corp. | 10.93M |
| Vaxil Bio Ltd. | 0.1137M |
| Waverley Pharma, Inc. | 4.099M |
| Goldcoast Resource Corp. | 1.580M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.8336M |
| Revenue (Quarterly) | 0.0081M |
| Total Expenses (Quarterly) | 0.8418M |
| EPS Diluted (Quarterly) | -0.0041 |
| Gross Profit Margin (Quarterly) | -143.2% |
| Profit Margin (Quarterly) | -10.29K% |
| Earnings Yield | -45.67% |
| Normalized Earnings Yield | -46.00 |